Patents by Inventor Shuang QI

Shuang QI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12310963
    Abstract: Provided is a novel PDGFR kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. Further provided are use and a method of the compound of formula (I) for preventing or treating conditions associated with PDGFR kinase activity, particularly use and a method for preventing or treating conditions associated with PDGFR? and/or PDGFR? kinase activity.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: May 27, 2025
    Assignee: Tarapeutics Science Inc.
    Inventors: Qing Song Liu, Jing Liu, Xi Xiang Li, Ao Li Wang, Feng Ming Zou, Cheng Chen, Qing Wang Liu, Juan Liu, Jiang Yan Cao, Wen Liang Wang, Shuang Qi, Wen Chao Wang, Bei Lei Wang, Li Wang
  • Patent number: 12162876
    Abstract: Described herein is a kinase inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug of the compound. Further described herein is a pharmaceutical composition containing the kinase inhibitor compound, as well as methods of using the compound to inhibit cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFR?, PDGFR?, and/or VEGFR2 kinase activity in cells or a subject, and methods for preventing or treating disorders related to cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFR?, PDGFR?, and/or VEGFR2 activity in a subject.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: December 10, 2024
    Assignee: Tarapeutics Science Inc.
    Inventors: Jing Liu, Qingsong Liu, Xuesong Liu, Beilei Wang, Cheng Chen, Ziping Qi, Wenchao Wang, Junjie Wang, Zongru Jiang, Wenliang Wang, Shuang Qi, Li Wang
  • Patent number: 12164838
    Abstract: An intelligent drawing-model checking method includes: acquiring a first drawing model and a second drawing model, determining an alignment base point according to the first drawing model and the second drawing model, and aligning the first drawing model and the second drawing model into a same reference coordinate system using the alignment base point; determining axis vectors in the first drawing model and the second drawing model according to a standard axis net, calculating a cosine value between the axis vectors, and rotationally aligning at least one of the first drawing model and the second drawing model according to the cosine value; and displaying lines and points in the first drawing model after the rotational alignment in a first color, displaying lines and points in the second drawing model after the rotational alignment in a second color, and checking the drawing models by color mixing distinguishing.
    Type: Grant
    Filed: December 24, 2021
    Date of Patent: December 10, 2024
    Assignee: SHENZHEN XUMI YUNTU SPACE TECHNOLOGY CO., LTD.
    Inventors: Shuang Qi, Qinghua Chen, Lianqiang Li, Jiadi Xu, Jia Wang
  • Publication number: 20240394423
    Abstract: An intelligent drawing-model checking method includes: acquiring a first drawing model and a second drawing model, determining an alignment base point according to the first drawing model and the second drawing model, and aligning the first drawing model and the second drawing model into a same reference coordinate system using the alignment base point; determining axis vectors in the first drawing model and the second drawing model according to a standard axis net, calculating a cosine value between the axis vectors, and rotationally aligning at least one of the first drawing model and the second drawing model according to the cosine value; and displaying lines and points in the first drawing model after the rotational alignment in a first color, displaying lines and points in the second drawing model after the rotational alignment in a second color, and checking the drawing models by color mixing distinguishing.
    Type: Application
    Filed: December 24, 2021
    Publication date: November 28, 2024
    Applicant: SHENZHEN XUMI YUNTU SPACE TECHNOLOGY CO., LTD.
    Inventors: Shuang QI, Qinghua CHEN, Lianqiang LI, Jiadi XU, Jia WANG
  • Publication number: 20220288064
    Abstract: Provided is a novel PDGFR kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. Further provided are use and a method of the compound of formula (I) for preventing or treating conditions associated with PDGFR kinase activity, particularly use and a method for preventing or treating conditions associated with PDGFR? and/or PDGFR? kinase activity.
    Type: Application
    Filed: August 14, 2020
    Publication date: September 15, 2022
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Qing Song LIU, Jing LIU, Xi Xiang LI, Ao Li WANG, Feng Ming ZOU, Cheng CHEN, Qing Wang LIU, Juan LIU, Jiang Yan CAO, Wen Liang WANG, Shuang QI, Wen Chao WANG, Bei Lei WANG, Li WANG
  • Publication number: 20220002287
    Abstract: The present invention relates to a kinase inhibitor, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention further relates to pharmaceutical compositions comprising the kinase inhibitor, as well as to using said compounds and compositions to inhibit cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGF, PDGF, and/or VEGFR2 kinase activity in cells or a subject, and/or to a use and method for preventing or treating disorders related to cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGF, PDGF, and/or VEGFR2 activity in a subject.
    Type: Application
    Filed: November 12, 2018
    Publication date: January 6, 2022
    Applicant: Tarapeutics Science Inc.
    Inventors: Jing LIU, Qingsong LIU, Xuesong LIU, Beilei WANG, Cheng CHEN, Ziping QI, Wenchao WANG, Junjie WANG, Zongru JIANG, Wenliang WANG, Shuang QI, Li WANG
  • Publication number: 20210346406
    Abstract: Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhibitor and uses and methods for inhibiting the activity of one or more tyrosine kinases selected from MST1 and a mutant thereof in a cell or subject and for preventing or treating a disease related to MST1 or a mutant thereof in a subject by using the compound or composition.
    Type: Application
    Filed: October 9, 2019
    Publication date: November 11, 2021
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Qingsong LIU, Jing LIU, Yun WU, Wenliang WANG, Beilei WANG, ZiPing QI, Junjie WANG, Wenchao WANG, Shuang QI, Li WANG
  • Patent number: 10793543
    Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: October 6, 2020
    Assignees: PRECEDO PHARMACEUTICALS CO., LTD, HEFEI GRACEVO BIO-MEDICINE CO., LTD
    Inventors: Qingsong Liu, Jing Liu, Qiang Wang, Beilei Wang, Feiyang Liu, Shuang Qi, Ziping Qi, Fengming Zou, Cheng Chen, Wenchao Wang, Chen Hu, Xiaochuan Liu, Wei Wang, Aoli Wang, Li Wang, Zhenquan Hu, Tao Ren
  • Patent number: 10669238
    Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 2, 2020
    Assignee: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Jing Liu, Qingsong Liu, Qianmao Liang, Yongfei Chen, Cheng Chen, Aoli Wang, Hong Wu, Kailin Yu, Wei Wang, Chen Hu, Wenchao Wang, Shuang Qi, Beilei Wang, Li Wang
  • Publication number: 20190084960
    Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.
    Type: Application
    Filed: March 28, 2017
    Publication date: March 21, 2019
    Applicants: PRECEDO PHARMACEUTICALS CO., LTD, HEFEI GRACEVO BIO-MEDICINE CO., LTD
    Inventors: Qingsong LIU, Jing LIU, Qiang WANG, Beilei WANG, Feiyang LIU, Shuang QI, Ziping QI, Fengming ZOU, Cheng CHEN, Wenchao WANG, Chen HU, Xiaochuan LIU, Wei WANG, Aoli WANG, Li WANG, Zhenquan HU, Tao REN
  • Publication number: 20190040013
    Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.
    Type: Application
    Filed: December 22, 2016
    Publication date: February 7, 2019
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Jing LIU, Qingsong LIU, Qianmao LIANG, Yongfei CHEN, Cheng CHEN, Aoli WANG, Hong WU, Kailin YU, Wei WANG, Chen HU, Wenchao WANG, Shuang QI, Beilei WANG, Li WANG